Safety, tolerability and preliminary efficacy of ALMB-0166 in patients with acute spine cord injury
Jinqian Liang, Wei Chen, Fang Zhou, Wenge Wang, Weixiang Kong, Pingping Chen, Juehua Jing, Haijiao Mao, Youliang Hao, Qingxi Wang, Chao Li, Deliang Yin, Miao Jin, Shaonan Ni, Wen You, Yanfeng Zhang, Guixing Qiu · 2026
Read Safety, tolerability and preliminary efficacy of ALMB-0166 in patients with acute spine cord injury by Jinqian Liang, Wei Chen, Fang Zhou, Wenge Wang, Weixiang Kong, Pingping Chen, Juehua Jing, Haijiao Mao, Youliang Hao, Qingxi Wang, Chao Li, Deliang Yin, Miao Jin, Shaonan Ni, Wen You, Yanfeng Zhang, Guixing Qiu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421776.txt.
Description
Jinqian Liang leads a seventeen-author team reporting first human results, in a 2026 paper, for an antibody drug aimed at the secondary damage that follows spinal cord injury. ALMB-0166 blocks channels on star-shaped support cells that otherwise leak ATP and glutamate, fuelling inflammation and further nerve death after the initial trauma.
Twenty-five patients with injuries between the third and seventh neck vertebrae enrolled within seventy-two hours. Twenty-four were treated: seventeen with the drug across five dose levels, and seven with placebo. Everyone also received standard care. Side-effect rates were similar between groups, and severe events were proportionally fewer in the drug group. Blood levels, immune reactions to the drug and early efficacy signals complete this safety-first report.
Catalog record
| CREATOR | Jinqian Liang, Wei Chen, Fang Zhou, Wenge Wang, Weixiang Kong, Pingping Chen, Juehua Jing, Haijiao Mao, Youliang Hao, Qingxi Wang, Chao Li, Deliang Yin, Miao Jin, Shaonan Ni, Wen You, Yanfeng Zhang, Guixing Qiu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |